CNS HIV ANTI-RETROVIRAL THERAPY EFFECTS RESEARCH (CHARTER) EXTENSION

CNS艾滋病毒抗逆转录病毒治疗效果研究(CHECURE)于2002年获得资助，目的是探索在高效抗逆转录病毒疗法(HAART)的背景下艾滋病毒神经并发症的变化情况。Charge(约翰·霍普金斯大学，Mt.西奈医学院、加州大学圣地亚哥分校、德克萨斯大学加尔维斯顿医学分校、华盛顿大学、华盛顿大学圣路易斯分校)代表了不同的参与者群体以及在神经艾滋病各个方面拥有专业知识的调查人员，他们能够标准化神经医学、神经心理学、精神病学、神经病和成像协议以及正在进行的质量保证程序。从特许项目中得出的两个关键结论是，尽管有效的艾滋病毒治疗大大降低了死亡率和非神经疾病的发病率，但艾滋病毒相关神经认知障碍(HAND)和周围神经病仍然非常普遍。 在Charge Expansion中，从最初的Charge纵向队列中选择了180名参与者(每个站点30名)进行进一步研究，目的是揭示脑脊液病毒学失败、低水平HIV复制、认知恶化和白质异常，以及正在进行的周围神经病。这些人将每年接受神经心理学、神经内科、实验室和神经病变评估。一部分参与者将完成每年一次的脑部核磁共振扫描。

The CNS HIV Antiretroviral Therapy Effects Research (CHARTER) was funded in 2002 with the aim of exploring the changing presentation of HIV neurological complications in the context of highly active antiretroviral therapy (HAART). The six performance sites of CHARTER (Johns Hopkins University, Mt. Sinai Medical School, University of California at San Diego, University of Texas Medical Branch at Galveston, University of Washington, Washington University at St. Louis), representing a diverse participant pool as well as investigators with expertise in various aspects of NeuroAIDS, were able to standardize neuromedical, neuropsychological, psychiatric, neuropathy, and imaging protocols along with on-going quality assurance procedures. Two key conclusions to emerge from the CHARTER project are that HIV-Associated Neurocognitive Disorders (HAND) and peripheral neuropathy remain highly prevalent despite effective HIV treatments that have significantly reduced mortality and non-neurologic morbidities. In CHARTER Extension, 180 participants (30 per site) from the original CHARTER longitudinal cohort have been selected for further study based on the goal of shedding light on CSF virologic failure, low-level HIV replication, worsening cognition and abnormal white matter, as well on-going peripheral neuropathy. These individuals will be assessed annually using well-established neuropsychological, neuromedical, laboratory, and neuropathy assessments. A subset of participants will complete annual brain MRI scans.